Ken Herrmann
MD
Chair, Nuclear Medicine
👥Biography 个人简介
Ken Herrmann at Essen led the VISION trial that established lutetium-177-PSMA-617 (pluvicto) as a treatment for metastatic castration-resistant prostate cancer, leading to FDA approval in 2022. This landmark trial demonstrated that PSMA-targeted radioligand therapy significantly improved radiographic progression-free survival and overall survival in heavily pretreated mCRPC, establishing theranostics as a new treatment paradigm for prostate cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Ken Herrmann 的研究动态
Follow Ken Herrmann's research updates
留下邮箱，当我们发布与 Ken Herrmann（University Hospital Essen）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment